

Gold Coast 2019 Investment SHOWCASE

The diversified investment conference for ASX listed companies



CONFERENCE SUPPORTER

TUESDAY 25 JUNE 2019

8.30am	Arrival Tea & Coffee	
9.00am	Welcome & Introduction Jaxon Crabb - Business Development Manager Vertical Events	
9.10am	Kazia Therapeutics Ltd Dr James Garner - Chief Executive Officer	KZA
9.30am	FYI Resources Ltd Roland Hill - Managing Director	FYI
9.50am	MyFiziq Ltd Vlado Bosanac - Chief Executive Officer	MYQ
10.10am	Retech Technology Co. Ltd Edward Slade - Consultant	RTE
10.30am	Regal Investment Fund Julian Babarczy - Portfolio Manager Regal Funds Management	RF1
10.50am	MORNING TEA	
11.30am	Anatara Lifesciences Ltd Steven Lydeamore - Chief Executive Officer	ANR
11.50am	Antisense Therapeutics Ltd Mark Diamond - Managing Director / CEO	ANP
12.10pm	Renascor Resources Ltd David Christensen - Managing Director	RNU
12.30pm	AdAlta Ltd Sam Cobb - CEO & Managing Director	1AD
12.50pm	Locality Planning Energy Holdings Ltd Damien Glanville - CEO & Joint Managing Director	LPE
1.10pm	LUNCH	
2.00pm	Matsa Resources Ltd Paul Poli - Managing Director	MAT
2.20pm	Blackstone Minerals Ltd Scott Williamson - Managing Director	BSX
2.40pm	NeuroScientific Biopharmaceuticals Ltd Brian Leedman - Chairman	NSB
3.00pm	BMG Resources Ltd Bruce McCracken - Managing Director	BMG
3.20pm	Strata-X Energy Ltd Ron Prefontaine - Executive Chairman	SXA
3.40pm	Data Driven Speculation to Maximise Mining Investment Tyson Keen - Chief Executive Officer Share Collective	
4.00pm	CONFERENCE DRINKS	
4.30pm	CONFERENCE CLOSE	

WEDNESDAY 26 JUNE 2019

8.30am	Arrival Tea & Coffee	
9.00am	Welcome & Introduction Jaxon Crabb - Business Development Manager Vertical Events	
9.10am	The ASX Resources Market – What It May Mean For The Rest Of 2019 Rob Murdoch - Executive Director Austex Daily Unique Research	
9.30am	Sienna Cancer Diagnostics Ltd Carl Stubbings - Non-Executive Director	SDX
9.50am	Venture Minerals Ltd Andrew Radonjic - Managing Director	VMS
10.10am	Altech Chemicals Ltd Shane Volk - CFO & Company Secretary	ATC
10.30am	ResApp Health Ltd Dr Tony Keating - Managing Director / CEO	RAP
10.50am	MORNING TEA	
11.20am	De.mem Ltd Andreas Kroell - Chief Executive Officer	DEM
11.40am	King Island Scheelite Ltd Johann Jacobs - Executive Chairman	KIS
12.00pm	OptiScan Imaging Ltd Darren Lurie - Executive Chairman	OIL
12.20pm	Meteoric Resources NL Dr Andrew Tunks - Managing Director	MEI
12.40pm	Oventus Medical Ltd Dan Parry - Chief Financial & Operations Officer	OVN
1.00pm	LUNCH	
2.00pm	Winchester Energy Ltd John Kopcheff - Non-Executive Chairman	WEL
2.20pm	Pioneer Resources Ltd David Crook - Managing Director	PIO
2.40pm	Panel Discussion: A Diversified Portfolio... The Way Ahead Stuart Mackenzie - Investment Advisor, Morgans Tyson Keen - Chief Executive Officer, Share Collective Brian Leedman - Investor Guru	
3.40pm	COMPETITION WINNERS ANNOUNCED	
4.10pm	CONFERENCE CLOSE	



Conference Wifi: **Marriott Wi-Fi**



Gold Coast 2019 Investment SHOWCASE

The diversified investment conference for ASX listed companies

Tuesday 25 & Wednesday 26 June 2019
Surfers Paradise Marriott Resort & Spa, QLD



Sponsored by: **share collective.**

Conference Supporter:

SHOWCASING COMPANIES: CLICK ON THE COMPANY'S LOGO TO BE DIRECTED TO THEIR WEBSITE



AdAlta Ltd (ASX:1AD)

AdAlta is focused on progressing its lead i-body candidate, AD-214, for the treatment of idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and for which there is a high-unmet medical need. AdAlta's is targeting 1-2 partnerships with its unique i-body platform that will bring in commercial revenue as partners look to access this technology. AdAlta recently completed a placement to Institutional and sophisticated investors in May/June 2019. For more information visit: www.adalta.com.au/



Altech Chemicals Ltd (ASX:ATC)

Altech Chemicals Ltd is aiming to become one of the world's leading producers of 99.99% (4N) high purity alumina (HPA) (Al₂O₃) through the construction and operation of a 4,500tpa HPA plant at Tanjung Langsat Industrial Complex, Johor, Malaysia. Feedstock for the HPA plant will be sourced from the Company's 100%-owned kaolin deposit at Meckering, Western Australia. HPA is a high-value, high margin and highly demanded product as it is the critical ingredient required for the production of synthetic sapphire. Synthetic sapphire is used in the manufacture of substrates for LEDs; semiconductor wafers used in the electronics industry; and scratch-resistant sapphire glass used for wristwatch faces, optical windows and smartphone components. An emerging use for HPA is as a coating for lithium-ion battery separators. There is no substitute for HPA in the manufacture of synthetic sapphire. Altech is fast-tracking the development of its HPA project after securing a 10-year off-take agreement with Mitsubishi for 100% of its proposed HPA production. For more information visit: www.altechchemicals.com



Anatara Lifesciences (ASX:ANR)

Anatara Lifesciences Ltd is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information visit www.anataralifesciences.com



Antisense Therapeutics Ltd (ASX:ANP)

About Antisense Therapeutics Ltd (ASX: ANP) is an Australian publicly listed biopharmaceutical company, developing and commercialising antisense pharmaceuticals for large unmet markets. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ:IONS), world leaders in antisense drug development and commercialisation. ANP's pipeline consists of ATL1102, an antisense inhibitor of CD49d, a subunit of VLA-4 (Very Late Antigen-4) that has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis and ATL1103 designed to block GHR production that successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly. The Company is currently conducting a Phase II clinical trial of ATL1102 in Duchenne Muscular Dystrophy patients at the Royal Children's Hospital, Melbourne. For more information visit: www.antisense.com.au/



Blackstone Minerals Ltd (ASX:BSX)

Blackstone Minerals Ltd is a Perth-based exploration company actively exploring the very high grade BC Cobalt Project in British Columbia, Canada. The first drill hole from the Company's maiden drilling program intersected 3.0% cobalt and 44g/t gold confirming Little Gem as one of the world's highest grade Cobalt exploration projects. The initial results are consistent with historic drilling and adit channel sampling which returned average grades of 3% cobalt and 20 g/t gold. The BC Cobalt Project covers a large land holding with 48 km of untested strike potential of geology analogous to the world class Bou-Azzer primary Cobalt district in Morocco and is favourably located less than 15 km along strike from the Bralorne-Pioneer mining complex (endowment of 4.4 Moz at 17 g/t Au). Blackstone is the first company in over 60 years to undertake systematic exploration for Cobalt at Little Gem and within the surrounding district with recent (August 2018) discoveries of visible gold and oxidised cobalt (erythrite) being the first in the region since prospectors discovered similar mineralisation at Little Gem in the 1930's. More recently, the company has entered into a binding term sheet for the exclusive option to acquire a 90% interest in the Ta Khoa Nickel Project in Vietnam. For more information, visit: www.blackstoneminerals.com.au



BMG Resources Ltd (ASX:BMG)

BMG Resources is an ASX-listed (BMG) minerals exploration company targeting lithium brine in Chile. Through a recently signed JV agreement with Chilean Lithium explorer Lithium Chile SpA, BMG is seeking to undertake exploration and development of three lithium brine projects located in the world's best lithium district, Atacama. This move into lithium is part of BMG's wider strategy to focus on battery minerals, in particular lithium and cobalt which are proving crucial in the EV revolution. In addition, BMG has a strategic free-carried interest in the Treasure copper-gold project in Crypus. For more information visit: www.bmgil.com.au/



De.mem Ltd (ASX:DEM)

De.mem is an Australian-Singaporean decentralised water and waste water treatment business that designs, builds, owns and operates turn-key water and waste water treatment systems for its clients. The Company operates in the industrial segment providing systems and solutions to customers from the mining, food & beverage, electronics, chemicals and oil & gas industries and in the municipal and residential segments. De.mem makes use of a portfolio of highly innovative, proven, disruptive and easy-to-scale membrane filtration technologies which are commercialized as a key component within the Company's water and waste water treatment systems. Some of the technologies were originally developed by the De.mem's partner in research & development, Singapore's Nanyang Technological University (NTU), and exclusively licensed to the Company. Through its wholly owned subsidiary De.mem-Akwa Pty Ltd (formerly: Akwa-Worx Pty Ltd), De.mem has a strong presence in Australia and an established customer base among the mining, infrastructure and food & beverage sectors. For more information visit: www.demembranes.com



FYI Resources Ltd (ASX:FYI)

FYI's corporate objective is to be Australia's first fully integrated high purity alumina (>99.99% Al₂O₃) production company utilising a non-traditional, alternative source to bauxite, being aluminous rich clay (Kaolin). FYI is developing a redesigned in-house refining process with demonstrated key technical and commercial advantages over the traditional bauxite supply. These benefits include significant capital reductions, substantially lower operating costs and an extremely low environmental footprint which contributes towards a sustainable operation. Having completed an extremely positive PFS and now undertaking BFS review, FYI is positioning itself as being a significant producer of 4N (99.99%) and 5N (99.999%) and addressing the rapidly developing and growing LED, electronic screens, scratch proof sapphire glass, semiconductor and other electronics, electric vehicle (EV), static power storage and other "new age" technologies and high specification applications. The foundation of FYI's HPA strategy is the superior quality aluminous clay (kaolin) deposit at Cadoux and the extremely efficient process design (integrating moderate temperature, atmospheric pressure HCl) flowsheet and >50 year mine life. FYI is progressing with its HPA Bankable Feasibility and continuing to develop relationships with HPA customers, end users and traders to finalise long term off-take agreements. For more information visit: www.fyiresources.com.au/



Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA)

Kazia Therapeutics Ltd is an innovative cancer-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop new treatment for several forms of cancer. Our lead program is GDC-0084, which is being developed to treat glioblastoma, the most common and most aggressive form of brain cancer. Licensed from Genentech in late 2016, GDC-0084 entered a phase II clinical trial in March 2018 and superior safety and tolerability data was announced in May 2019. Preliminary efficacy data from the trial is expected in 4Q 2019. In addition, three other studies are underway in the US in other forms of brain cancer, including an aggressive form of childhood brain cancer. Our second therapeutic, TRX-E-002-1 (Cantrixil), is being developed to treat ovarian cancer and is currently undergoing a phase I clinical trial in Australia and the United States. Initial data was presented at the AACR annual conference in April 2019 and the study is expected to conclude later in 2019. For more information visit: www.kaziatherapeutics.com



King Island Scheelite Ltd (ASX:KIS)

King Island is the most western large island in the Bass Strait, located between Victoria and Tasmania. The Dolphin Project is situated on the south east coast of the island, near the mining town of Grassy. The Dolphin Tungsten Mine operated between 1917 and 1992, when it was closed due to extremely low tungsten prices, rather than a lack of reserves. Over the last few years, KIS has concentrated on optimising a redevelopment strategy for the Dolphin Tungsten Project, which contains a JORC 2012 compliant Mineral Reserves of 3.14Mt at a grade of 0.73% WO₃ (at 0.2% cut-off). Mineral Resources, including the Mineral Reserves, total 9.6Mt at a grade of 0.90% WO₃ (at 0.2% cut-off). The current development plan envisages an 8-year open cut mine producing a concentrate for supply into the Ammonium Paratungstate market. For more information visit: www.kingislandscheelite.com.au/



Locality Planning Energy Holdings Ltd (ASX:LPE)

Locality Planning Energy (LPE) is an Australian electricity and utility supplier offering innovative, cost-effective supply solutions and exceptional, QLD-based customer service. Founded in 2012, by energy market experts Ben Chester and Damien Glanville, LPE now have over 25,000 customers across several sectors including residential, commercial, strata and new construction. With their head office and call-centre based in regional QLD (Maroochydore, Sunshine Coast), LPE are a unique offering in the energy market which has led to significant and rapid growth. The company's potential has been verified by their securing of a debt facility from investment giant, BlackRock in October 2018. LPE is currently expanding geographically and continuing to diversify its product offering. For more information visit: www.localityenergy.com.au/



Matsa Resources Ltd (ASX:MAT)

Matsa Resources is an ASX listed explorer who has become a gold producer following the acquisition and development of the Fortitude gold mine. Fortitude lies within the Lake Carey gold project south of Laverton, and is only one of a pipeline of quality projects within Australia and central Thailand. With an extensive exploration programme currently underway at Lake Carey, exciting times exist with potentially significant new discoveries pending. Importantly Matsa have recently acquired the Red October Gold mine also in Lake Carey which boosts mining potential within the area. Matsa remains in a strong financial position with cash and liquid assets. The Company aims not only to increase shareholder wealth through the discovery and development of minerals, but to do it in a socially and environmentally responsible way, utilising world best practices. For more information visit: www.matsa.com.au/

Follow us on Twitter: @VEEvents_RIU

Follow us on Instagram: [instagram.com/verticalevents](https://www.instagram.com/verticalevents)

Vertical Events Pty Ltd

Suite 13-14, 186 Hay Street Subiaco WA 6008 | PO Box 1153 Subiaco WA 6904

T: (61 8) 9388 2222 | E: info@verticalevents.com.au | W: www.verticalevents.com.au



Gold Coast 2019 Investment Showcase

The diversified investment conference for ASX listed companies

Tuesday 25 & Wednesday 26 June 2019
Surfers Paradise Marriott Resort & Spa, QLD



Sponsored by:



share collective.



Conference Supporter:
AUTOMIC GROUP

SHOWCASING COMPANIES: CLICK ON THE COMPANY'S LOGO TO BE DIRECTED TO THEIR WEBSITE



Meteoric Resources NL (ASX:MEI)

Meteoric Resources is focused on gold exploration following its recent 100% acquisition of the Jurueña and Novo Astro Gold Projects in the state of Matto Grosso in Central Brazil. The projects are located within the highly prospective Alta Floresta Belt which is home to majors including Vale and AngloAmerican. Meteoric is shortly to commence its initial drilling program targeting the two most advanced Jurueña prospects, Dona Maria and Querosene which host a combined high-grade JORC 2012 Mineral Resource Estimate of 436,000t @ 14.7g/t for 205,000 Au. For more information visit: www.meteoric.com.au/



MyFiziq Ltd (ASX:MYQ)

MyFiziq is a revolutionary mobile application developed and patented to measure and track the human form via a smart phone. We embed our technology in a partner's application, using images captured from your smartphone to create a representation of an individual in the form of a 3D avatar with accurate circumference measurements and body composition. Partners embed our SDKs (Software Development Kits) into their new or existing apps, and then customize the experience to satisfy their branding requirements. MyFiziq is an augments of current technologies, rather than a disruptor. We partner with highly scalable existing applications and provide our partners with a deeper insight into the data they currently retrieve from their users. When consumers want to track their changes from diet or training or simply buy insurance or clothing online, the end result is a drive toward understanding an individual's dimensions or the changes they are undergoing. MyFiziq provides that missing link in other ecosystems. For more information visit: www.myfiziq.com/



NeuroScientific Biopharmaceuticals Ltd (ASX:NSB)

NeuroScientific Biopharmaceuticals Ltd (ASX:NSB) is a biotech company focused on developing novel peptide-based drugs, called Emtins, which have the potential to treat neurodegenerative conditions. Emtin peptides are modelled on the active sites of a protein expressed in the brain following brain injury. NSB's lead peptide candidate, EmtinB, is most advanced as a treatment for Alzheimer's disease. EmtinB has been shown to induce the survival and regrowth of neurons through binding to specific receptors expressed by neuronal cells. The peptide offers a novel therapeutic treatment pathway for neurodegenerative diseases that are currently without effective treatment options, such as Alzheimer's disease. For more information visit: www.neuroscientific.com/



Optiscan Imaging Ltd (ASX:OIL)

Optiscan Imaging Ltd (ASX:OIL) is a global leader in the development of endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Our technology enables real-time, in vivo imaging at the cellular level in human and animal tissue and is used by leading research institutions and hospitals in North America, Europe, Asia and Australia. For more information visit: www.optiscan.com/



Oventus Medical Ltd (ASX:OVN)

Oventus Medical Ltd (ASX:OVN) is an Australian medical device company and is listed on the Australian Securities Exchange. It offers a new treatment modality for obstructive sleep apnoea (OSA) via its Airway Technology and its mission is to be a global leader in the treatment of snoring and OSA. What makes Oventus unique is its patented airway design, allowing for breathing through its O₂Vent™ oral devices to bypass obstructions of the nose, soft palate and tongue that can contribute to snoring and OSA. The O₂Vent™ is bridging the gap between Oral Appliance and CPAP therapy to enhance treatment outcomes, including for CPAP intolerant sleep apnoea sufferers. For more information visit: www.o2vent.com/



Pioneer Resources Ltd (ASX:PIO)

Pioneer Resources Ltd is a dynamic, diversified exploration and development company with a focus on key demand-driven minerals in the Eastern Goldfields of Western Australia. Our project portfolio includes; the 100%-owned Pioneer Dome Project, where the Company recently completed mining Australia's first caesium deposit and is now drilling other caesium and lithium targets. The Company also has the 100%-owned Golden Ridge Project with nickel sulphide and cobalt targets recently delivering significantly mineralised intersections. Pioneer also has a portfolio of free-carried exploration joint ventures, including: with Northern Star at the Acra Gold Project and with Novo at the Kangan Gold Project. For more information visit: www.pioneerresources.com.au/



15 YEARS

Regal Investment Fund (ASX:RF1)

Regal Funds Management was founded in 2004 and specialises in managing alternative investment strategies with a primary focus on long/short investment strategies. Regal has been investing in alternatives since 2004 and possesses a 15-year award winning track record of managing alternative investment strategies. Regal's Investment Team members have, on average, over 10 years' experience in financial markets both in Australia and overseas, with extensive experience of investing through multiple market cycles. The Investment Team has experience on the buy and sell side, fundamental investing, sales and research, long-side and hedge fund investing, as well as investment banking and capital markets. Regal manages capital for a range of clients including private banks, financial planning groups, asset consultants, offshore pension funds, family offices and high net worth individuals. For more information visit: www.regalfm.com/site/content/



Renascor Resources Ltd (ASX:RNU)

Renascor Resources is an Adelaide-based exploration and development company. Its flagship project is the Siviour Graphite Project – Australia's largest graphite deposit and among the largest graphite deposits in the world. For more information visit: www.renascor.com.au/



ResApp Health Ltd (ASX:RAP)

ResApp Health Ltd (ASX:RAP) is developing digital healthcare solutions to assist doctors and empower patients to diagnose and manage respiratory disease. We are creating easy to use, affordable, clinically validated and regulatory approved diagnostic tools that only require a smartphone. Our solutions are designed to be easily integrated into existing telehealth solutions and we are also working on apps to provide respiratory disease diagnosis and management directly to consumers and healthcare providers. ResApp is similarly developing an app for the diagnosis of sleep apnea. ResApp was founded in September 2014 to commercialise technology developed by Associate Professor Udantha Abeyratne at The University of Queensland who has received funding by the Bill and Melinda Gates Foundation. For more information visit: www.resapphealth.com.au/



RETECH

Retech Technology Co. Ltd (RTE:ASX)

Retech Technology Co., Limited is China's leading e-learning services and technology provider. The market for corporate e-learning in China is in an early, growth stage, and is estimated at approximately US\$1.5bn in size, compared to a US\$100bn global corporate e-learning market. Retech provides its clients with high quality, customized online training solutions and training management solutions. Retech's products include e-learning solutions, learning analytics, customized and pre-prepared courses from our library of high quality training courses, ESG reporting and training for our clients, and online language training programs. Customers include Bank of China, Ping An Insurance and Mercedes Benz. Based in Shanghai, Retech has over 260 staff, 80% of which are involved in courseware development and R&D. In the year to December 2018, our net profit was A\$ 9.95mn equivalent, growing 30% over 2017. As at end May 2019, our market capitalisation was A\$96 million. For more information visit: www.retech-rte.com/ or contact investors@retech-rte.com



Sienna Cancer Diagnostics Ltd (ASX:SDX)

Sienna Cancer Diagnostics Ltd is an Australian medical technology company with operations in the United States, Europe, Asia, Latin America and Australia. Sienna's strength lies in the identification, development and commercialisation of novel IVD technologies that satisfy an unmet clinical need in the pathology diagnostics market. The Company has taken its first product, an IVD test for the biomarker hTERT, from research, through development, manufacturing, product registration, and market launch through a growing network of distribution partners. Sienna's most recent technology acquisition, SIEN-NET™, is a unique technology for the capture and isolation of target analytes in liquid biopsy samples. The sample preparation technology can more accurately and rapidly prepare liquid biopsy samples for the testing of a range of clinically useful biomarkers including exosomes, lipids, proteins, and other molecular targets of interest. Sienna is actively seeking new diagnostic technologies to bring into their pipeline to leverage their existing knowledge, capability and infrastructure for further sustainable growth. For more information visit: www.siennadiagnostics.com.au/



Strata-X Energy Ltd (TSX.V:SXE)(ASX:SXA)

Strata-X Energy Ltd is an independent oil and gas company listed on the Australian Securities Exchange and the TSX-Venture Exchange. The Company's focus is on its 100% owned 1,129,000 acre Serowe CSG Project located in the heart of the Kalahari Basin in the Republic of Botswana. Over 6 TCF of prospective gas resource, net to Strata-X, has been independently certified for the Project. The Company's planned 2019/20 appraisal programmes target the capability to progressively convert this huge prospective gas resource into reserves, not only for the benefit of Strata-X shareholders, but also to the benefit of the emerging economies in southern Africa that surround the Serowe CSG Project. For more information visit: www.strata-x.com/



Venture Minerals Ltd (ASX:VMS)

Venture Minerals Ltd (ASX:VMS) has secured an off-take agreement for the Riley Iron Ore Mine and is updating the feasibility study for an upcoming decision to recommence mining following a significant sustained recovery in the iron ore price. At the neighbouring Mount Lindsay Tin-Tungsten Project in North-West Tasmania, higher Tin prices and the recognition of Tin as a fundamental metal to the battery revolution has refocused Venture's approach to developing Mount Lindsay. Already one of the world's largest undeveloped Tin deposits, the Company recently commissioned an Underground Scoping Study on Mount Lindsay that will leverage off the previously completed feasibility work. Venture is also exploring in Western Australia and has delivered early success with the maiden drilling program at Thor intersecting massive sulfides confirming the Copper-Lead-Zinc target is a 20 kilometre VMS style system. Other WA assets include a strategic landholding along strike to the world class Golden Grove Copper-Zinc-Gold Mine, the Kulin PGE-Nickel-Copper Project and the Caesar Nickel-Copper-Gold Project. For more details, visit: www.ventureminerals.com.au



Winchester Energy Ltd (ASX:WEL)

Winchester Energy Limited (ASX: WEL) is an Australian Securities Exchange (ASX) listed oil and gas explorer and producer with approximately 17,402 net acres in the highly productive Eastern Shelf of the Permian Basin in Texas, USA. The acreage offers a host of targets ('stacked pay') with prospective Cline and Barnett Shale unconventional oil opportunities at shallow depth together with appreciable conventional oil and gas production from the Ellenburger Formation and Strawn Formation at slightly greater depths. Winchester management have a proven track record in realising value from unconventional and conventional oil and gas developments with the Company already controlling a large acreage position with low holding costs and flexible drilling commitments together with a strong production profile in the prolific Permian Basin. For more information visit: www.winchesterenergyltd.com/



Follow us on Twitter: @VEEvents_RIU



Follow us on Instagram: [instagram.com/verticalevents](https://www.instagram.com/verticalevents)

Suite 13-14, 186 Hay Street Subiaco WA 6008 | PO Box 1153 Subiaco WA 6904
T: (61 8) 9388 2222 | E: info@verticalevents.com.au | W: www.verticalevents.com.au

Vertical Events Pty Ltd

